Indian version of Gleevec, Indian Gleevec purchasing agent 13621079267 Gleevec price

> > < < . _b>
b>
=_b> > > <
=_b> , b>[Indications/Function Indications]
For the treatment of chronic myeloid cells Patients with leukemia () in the blast phase, accelerated phase or chronic phase after failure of interferon therapy, and patients with malignant gastrointestinal stromal tumors () that cannot be surgically resected or metastasized.
, b>[Specifications and models]
.* (Gleevec)
, b>[Usage and dosage]
Starting dose: for the blast phase and accelerated phase of chronic myelogenous leukemia For patients, the recommended dose of imatinib mesylate is /day. For patients in the chronic phase who have failed interferon therapy, and for patients with malignant gastrointestinal stromal tumors that cannot be surgically removed or metastasized (), the recommended dose is /day, They are all taken orally once a day and should be taken with a meal and a large glass of water. As long as it is effective, it should be continued. If the blood picture permits and there are no serious adverse drug reactions, the dose may be considered to be increased from /day to /day, or from /day to /day (taken in divided doses) under the following circumstances: disease progression, failure to treat after at least one month Satisfactory hematological response was obtained, and the hematological response that had been achieved disappeared again. The dose must be adjusted in the following circumstances: If serious non-hematological adverse reactions (such as severe water retention) occur during treatment, the drug should be discontinued until the adverse reactions disappear, and then the dose will be adjusted according to the severity of the adverse reactions. Dosage adjustment in case of severe liver toxicity: If the increase in bilirubin exceeds the upper limit of the normal range or the increase in transaminases exceeds the upper limit of the normal range, the drug should be discontinued until the above indicators drop to or below the upper limit of the normal range respectively.
, b>【Adverse reactions】
Unclear.
, b>【Contraindications】
Contraindicated for those who are allergic to the active substance of this medicine or any excipients.
, b>【Precautions】
Patients who are at risk of cardiovascular disease or have heart disease should be closely monitored. During treatment, patients with obvious symptoms of heart failure should be comprehensively examined and treated according to clinical symptoms. Treat accordingly. It is recommended to check the complete blood count once a week in the first month of treatment with imatinib mesylate, once every two weeks in the second month, and then as needed (for example, once every month). If severe neutropenia or thrombocytopenia occurs, the dose should be adjusted (see [Dosage and Administration]). Liver function (transaminases, bilirubin, and alkaline phosphatase) should be checked before starting treatment and then monthly or as determined by clinical circumstances, and the dose should be adjusted if necessary. Patients with mild, moderate, and severe hepatic impairment should have their blood and liver enzymes monitored.
, b>【Pediatric Medication】
Unclear.
, b>[Medication for elderly patients]
It is not clear yet.
, b>[Drugs for pregnant and lactating women]
It is not clear yet.
, b>【Drug Interactions】
Drug interactions may occur if used together with other drugs. Please consult your physician or pharmacist for details.
, b>【Drug overdose】
Unclear.
, b>【Pharmacology and Toxicology】
Unclear.
, b>[Pharmacokinetics]
The dose of imatinib mesylate is within the - range, and there is a proportional relationship between the increase in the average area under the curve () and the dose. The cumulative amount of drug after repeated administration can reach .-.times that of steady state. Pharmacokinetic studies in adult populations have shown that gender has no effect on pharmacokinetics, and the effect of body weight is negligible.
, b>【Storage】
Sealed.
, b>[Packaging]
.*/box.